Smad1 promotes the tumorigenicity and drug resistance of glioblastoma by dissociating p300 from p53
Abstract：Acetylation is a key step in the activation of p53, but the regulatory mechanisms of p53 acetylation in glioblastoma (GBM) remain poorly understood. This study indicates that p53 acetylation is a favorable prognostic biomarker in GBM regardless of the p53 status, and the key negative regulator of p53 acetylation, Smad1, participates in this process.
Machine-generated Keywords：
Publication Date：2025-04-08
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：1( 132 )